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1. TEIPP T cells are an ideal platform for the treatment of TAP-deficient tumors due to their efficient 
thymic selection, their effective activation upon peptide vaccination and their specific recognition of 
TAP-deficient cells (this thesis) 
 
2. The lack of TEIPP T cell activation in mice bearing a MHC-I
low
 tumor can be explained by direct priming, 
requiring  high levels of both MHC-I and antigen, being the major pathway of TEIPP T cell activation 
(this thesis) 
 
3. The Trh4 peptide acquires a unique conformation with the H2-D
b
 molecule, which is essential for T cell 
recognition (this thesis) 
 
4. The size of an intratumoral immune cell population does not always reflect the importance of that 
particular population for immune mediated  control of tumor growth  (this thesis) 
 
5. Characterization of the molecular mechanism underlying the lack or downregulation of HLA class I 
expression, seems to be a crucial step predicting clinical responses to T cell mediated immunotherapy. 
This will aid the selection of strategies that could condition patients for response. (Thor Straten P and 
Garrido F, J Immunother Cancer (2016)) 
 
6. When targeting a suitable epitope, the levels of MHC-I may not be as an important factor for cancer 
eradication as previously believed, which is encouraging considering that many tumors express low 
levels of MHC-I (Textor et al., Journal of Experimental Medicine (2016)) 
 
7. Loss of IFN-γ signaling in tumor cells may represent a common mechanism for tumor resistance to 
immune checkpoint therapy. As a result, MHC-I levels are strongly reduced in these tumors, urging the 
need to identify novel strategies to target these MHC-I
low
 tumors (based on Gao et al., Cell (2016) and 
Zaretsky et al., New England Journal  of Medicine (2016)) 
 
8. Ultimately, innate immune pathway agonists might promote de novo activation and recruitment of 
anti-tumor T cells, which still may become held in check by negative regulatory pathways such as PD-
1/PD-L1 interactions (Corrales et al., Cell Research (2017)) 
 
9. De wetenschap moet beter communiceren naar t algemene publiek 
 
10. Life at its best is an adventure, a voyage of discovery (Peter Doherty, The beginner’s guide to winning 
the Nobel Prize, advice for young scientists (2008)) 
 
11. Compromissen zijn soms nodig om iets te bereiken. Met je hakken in het zand is het lastig lopen 
(Loesje) 
